TELA Bio (TELA) Stock Price, News & Analysis

Company Overview

TELA Bio, Inc. (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems. Its flagship offering, TELAPro™, is an acellular dermal matrix designed for abdominal wall reconstruction and complex soft tissue repair. In addition, TELA Bio markets fibrin sealant systems and surgical films that serve as adjunctive tools for hemostasis and tissue regeneration across a variety of surgical and wound care settings.

Operating primarily in the United States, TELA Bio collaborates with surgeons, wound care specialists and research institutions to advance clinical protocols and broaden the applications of its platform technologies. Its manufacturing facility in Plymouth, Minnesota, adheres to rigorous quality and regulatory standards, supporting scalable production. Guided by a leadership team experienced in medical devices, biomaterials and commercial operations, TELA Bio is focused on expanding clinical adoption and growing its product pipeline in the regenerative medicine market.

Key Stats

• Today's Range: $1.56 to $1.70
• 50-Day Range: $1.47 to $2.14
• 52-Week Range: $0.86 to $3.26
• Volume: 39,397 shs
• Average Volume: 82,680 shs
• Market Capitalization: $62.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Moderate Buy

TELA Bio Stock Analysis - MarketRank™

TELA Bio scored higher than 56% of companies evaluated by MarketBeat, and ranked 518th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

TELA Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

TELA Bio has a consensus price target of $4.50, representing about 184.8% upside from its current price of $1.58.

Amount of Analyst Coverage

TELA Bio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for TELA Bio are expected to grow in the coming year, from ($1.37) to ($0.66) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TELA Bio is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TELA Bio is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

TELA Bio has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.12% of the float of TELA Bio has been sold short.

Short Interest Ratio / Days to Cover

TELA Bio has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in TELA Bio has recently decreased by 7.99%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TELA Bio does not currently pay a dividend.

Dividend Growth

TELA Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.12% of the float of TELA Bio has been sold short.

Short Interest Ratio / Days to Cover

TELA Bio has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in TELA Bio has recently decreased by 7.99%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

TELA Bio has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for TELA Bio this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added TELA Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TELA Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.70% of the stock of TELA Bio is held by insiders.

Percentage Held by Institutions

94.35% of the stock of TELA Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TELA Stock Analysis - Frequently Asked Questions

How have TELA shares performed this year?

TELA Bio's stock was trading at $3.02 at the beginning of 2025. Since then, TELA shares have decreased by 47.7% and is now trading at $1.58.

How were TELA Bio's earnings last quarter?

TELA Bio, Inc. (NASDAQ:TELA) announced its earnings results on Monday, August, 11th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.04. The company earned $20.20 million during the quarter, compared to analyst estimates of $20.67 million. TELA Bio had a negative trailing twelve-month return on equity of 329.48% and a negative net margin of 54.12%.
Read the conference call transcript.

When did TELA Bio IPO?

TELA Bio (TELA) raised $60 million in an IPO on Friday, November 8th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Who are TELA Bio's major shareholders?

Top institutional investors of TELA Bio include Stonepine Capital Management LLC (5.27%), Geode Capital Management LLC (0.85%), JPMorgan Chase & Co. (0.15%) and Destiny Wealth Partners LLC (0.13%). Insiders that own company stock include Orbimed Advisors Llc, Opaleye Management Inc, Antony Koblish, Roberto Cuca, Paul Talmo and Gregory A Firestone.
View institutional ownership trends.

How do I buy shares of TELA Bio?

Shares of TELA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TELA Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TELA Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX).

Company Calendar

• Last Earnings: 8/11/2025
• Today: 9/12/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:TELA
• CIK: 1561921
• Web: www.telabio.com
• Phone: 484-320-2930
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for TELA Bio: $4.50
• High Price Target: $7.00
• Low Price Target: $2.00
• Potential Upside/Downside: +184.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.84 million
• Net Margins: -54.12%
• Pretax Margin: -54.20%
• Return on Equity: -329.48%
• Return on Assets: -57.34%

Debt

• Debt-to-Equity Ratio: 4.14
• Current Ratio: 3.19
• Quick Ratio: 2.59

Sales & Book Value

• Annual Sales: $69.30 million
• Price / Sales: 0.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.72 per share
• Price / Book: 2.19

Miscellaneous

• Outstanding Shares: 39,620,000
• Free Float: 37,754,000
• Market Cap: $62.60 million
• Optionable: Optionable
• Beta: 0.84